2 Top Growth Stocks to Buy Right Now Without Any Hesitation

Eli Lilly has just begun tapping into the massive opportunity in chronic weight management. Intuitive Surgical can bounce back thanks to innovation, a strong moat, and a large addressable market.

The Motley Fool • Jul 24, 2026

Intuitive Shares Vision for an AI-Enabled Future of Healthcare

SUNNYVALE, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, will outline its vision for how artificial intelligence (AI) can help shape the future of surgical care and address key healthcare challenges at the Society of Robotic Surgery's (SRS) annual conference in Hollywood, Florida.

GlobeNewsWire • Jul 23, 2026

Wall Street Analysts Think Intuitive Surgical (ISRG) Is a Good Investment: Is It?

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Zacks Investment Research • Jul 23, 2026

Why Intuitive Surgical, Inc. (ISRG) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jul 23, 2026

Bet on 5 Top-Ranked Stocks With Rising P/E

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Zacks Investment Research • Jul 23, 2026

ISRG vs. ABT: Which MedTech Giant Is the Smarter Investment Now?

ISRG's expanding robotic surgery ecosystem and innovation pipeline give it an edge over Abbott for investors seeking stronger long-term MedTech growth.

Zacks Investment Research • Jul 23, 2026

Can ISRG Maintain Its Premium Valuation Amid Slower Procedure Growth?

Intuitive Surgical's valuation has eased as U.S. procedure growth slows, but margin gains, AI software expansion and global growth could support its premium.

Zacks Investment Research • Jul 22, 2026

ISRG Growth Story Hinges on Da Vinci 5, Ion and Recurring Revenue

Intuitive Surgical's growth rests on da Vinci 5, Ion, SP and digital tools as recurring revenue rises and procedure risks persist.

Zacks Investment Research • Jul 22, 2026

ISRG Trends Point to AI, Lung Biopsy Growth and Margin Pressure

ISRG's growth is fueled by robotic surgery, Ion lung biopsy and AI tools, while tariffs, product mix and softer demand pressure margins.

Zacks Investment Research • Jul 22, 2026

Is ISRG Stock Worth Buying as Growth Stays Strong but Risks Rise

ISRG's strong procedure growth, recurring revenue and cash position support its case, but tariffs, mix shifts and placement risks cloud the outlook.

Zacks Investment Research • Jul 22, 2026